La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Ropinirole And NotErwan Bezard

List of bibliographic references

Number of relevant bibliographic references: 9.
Ident.Authors (with country if any)Title
000592 Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa
000738 Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
000847 M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada]Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate
000917 Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
000965 Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada]Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease
000967 Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis]Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis
000A89 Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada]Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials
000C12 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
000C28 D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada]Ropinirole and pramipexole, the new agonists

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022